Australia's most trusted source of pharma news
New migraine drugs expected in 2018
Posted 14 December 2017
A new class of biological migraine drugs is expected to land in Australia next year with strong reimbursement prospects for sponsors.
Novartis' and Amgen's Aimovig (erenumab) is expected to appear on the ARTG in 2018 and will be followed by Lilly's galcanezumab.
Aimovig was filed with the FDA and in Europe in mid- 2017, with strong data supporting the filings since being released. The FDA is expected to make a decision by May 2018.
The most recent data, published in the New England Journal of Medicine (NEJM), found patients "experienced a significant reduction in mean monthly migraine days and were significantly more likely to achieve a 50 per cent or greater reduction in monthly migraine days than those taking placebo".
Aimovig is the first calcitonin gene-related peptide (CGRP) inhibitor to be filed globally, although Lilly is hoping to be not far behind.
Its biologic galcanezumab was filed with the FDA this week, and is among the 20 new drugs and drug extensions Lilly is hoping to launch over the coming decade.
Lilly's General Manager, Australia and New Zealand, Libby Driscoll said the company aimed to "have at least one if not two and maybe more new products or new indications launched every year for the next decade".
For Driscoll, galcanezumab falls into the "immunology, neurodegenerative and pain" bucket of therapies - one of three areas the pharmaco is looking to specialise in.
Galcanezumab represents the first of three investigational, non-opioid treatments in development as part of Lilly's overall pain portfolio. The portfolio also includes lasmiditan for the acute treatment of migraine and tanezumab, developed in partnership with Pfizer, for the treatment of osteoarthritis, chronic low back pain and cancer pain.
Also looking to capitalise on CGRP inhibitors is Teva with its migraine drug fremanezumab expected to be filed shortly, while Alder BioPharmaceuticals also has a contender with its eptinezumab.
Megan Brodie
megan.brodie@lushmedia.com.au
Posted 14 December 2017
A new class of biological migraine drugs is expected to land in Australia next year with strong reimbursement prospects for sponsors.
Novartis' and Amgen's Aimovig (erenumab) is expected to appear on the ARTG in 2018 and will be followed by Lilly's galcanezumab.
Aimovig was filed with the FDA and in Europe in mid- 2017, with strong data supporting the filings since being released. The FDA is expected to make a decision by May 2018.
The most recent data, published in the New England Journal of Medicine (NEJM), found patients "experienced a significant reduction in mean monthly migraine days and were significantly more likely to achieve a 50 per cent or greater reduction in monthly migraine days than those taking placebo".
Aimovig is the first calcitonin gene-related peptide (CGRP) inhibitor to be filed globally, although Lilly is hoping to be not far behind.
Its biologic galcanezumab was filed with the FDA this week, and is among the 20 new drugs and drug extensions Lilly is hoping to launch over the coming decade.
Lilly's General Manager, Australia and New Zealand, Libby Driscoll said the company aimed to "have at least one if not two and maybe more new products or new indications launched every year for the next decade".
For Driscoll, galcanezumab falls into the "immunology, neurodegenerative and pain" bucket of therapies - one of three areas the pharmaco is looking to specialise in.
Galcanezumab represents the first of three investigational, non-opioid treatments in development as part of Lilly's overall pain portfolio. The portfolio also includes lasmiditan for the acute treatment of migraine and tanezumab, developed in partnership with Pfizer, for the treatment of osteoarthritis, chronic low back pain and cancer pain.
Also looking to capitalise on CGRP inhibitors is Teva with its migraine drug fremanezumab expected to be filed shortly, while Alder BioPharmaceuticals also has a contender with its eptinezumab.
Megan Brodie
megan.brodie@lushmedia.com.au
Drought, fire and now virus cut chance of PBS relief.
Don't do it for the accolades; do it for your kids.
New forms of rotavirus vaccine Rotarix.